Lozanski Gerard, Heerema Nyla A, Flinn Ian W, Smith Lisa, Harbison Jennifer, Webb Jennifer, Moran Mollie, Lucas Margaret, Lin Thomas, Hackbarth Marcy L, Proffitt John H, Lucas David, Grever Michael R, Byrd John C
Department of Pathology, Ohio State University, Columbus, OH 43210, USA.
Blood. 2004 May 1;103(9):3278-81. doi: 10.1182/blood-2003-10-3729. Epub 2004 Jan 15.
The presence of p53 mutation or deletion predicts for poor response to conventional therapy in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti-CD52 antibody alemtuzumab was effective in this patient group. Thirty-six patients with fludarabine-refractory CLL were treated with alemtuzumab, 15 (42%) of whom had p53 mutations or deletions. Clinical responses in patients with p53 mutations, deletions, or both were noted in 6 (40%) of 15 versus 4 (19%) of 21 of patients without. The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.
p53突变或缺失的存在预示着慢性淋巴细胞白血病（CLL）患者对传统治疗反应不佳。我们试图确定人源化抗CD52抗体阿仑单抗在该患者群体中是否有效。36例对氟达拉滨耐药的CLL患者接受了阿仑单抗治疗，其中15例（42%）存在p53突变或缺失。有p53突变、缺失或两者皆有的患者中，临床缓解率为15例中的6例（40%），而无p53突变或缺失的21例患者中为4例（19%）。该亚组患者的中位缓解持续时间为8个月（范围3 - 17个月）。这些数据表明，阿仑单抗可能是治疗伴有p53突变或缺失的CLL患者的有效疗法。
